Showcasing the future of ophthalmic research at ARVO 2025:

ZEISS Research Data Platform launch - a cloud-based, AI-driven technology solution designed to accelerate discoveries, integrating research and clinical data, and simplifying research workflows.ZEISS's collaboration with Boehringer Ingelheim - championing data-driven, personalized care through ZEISS's ongoing research partnership with Boehringer Ingelheim; hear from industry experts during special presentations at the ZEISS booth #1729 and the Boehringer Ingelheim booth #1629. 

Showcasing at ASCRS 2025:

More than 2 million cases planned with ZEISS VERACITY Surgery Planner: Growing use of one of the leading digital planning solutions for cataract surgery in the U.S. is a testament to the increased adoption of the ZEISS Cataract Workflow digital solutions by surgeons.ZEISS MEL 90 broadens refractive treatment portfolio: U.S. availability of both the ZEISS MEL 90 and ZEISS VISUMAX 800 extends the company's LVC market leadership with treatments for myopia, hyperopia, and mixed astigmatism.Enhanced cataract portfolio with DORC and FCI: Showcasing cataract solutions from DORC and FCI for the first time in the ZEISS booth #1501.  

JENA, Germany, March 27, 2025 /CNW/ -- ZEISS Medical Technology announced today that the ILM staining dye ILM-Blue® from DORC (Dutch Ophthalmic Research Center (International) B.V.) has received National Medical Products Administration (NMPA) approval in China, marking a significant milestone in the product's global journey.

"ZEISS and DORC are committed to supporting surgeons in the China market with the latest innovation and tools that create a higher standard of care and better patient experience," says Pierre Billardon, Head of Business Sectors Surgery Posterior Segment at ZEISS Medical Technology and CEO of DORC International. "The global success of ILM-Blue underscores the company's commitment to providing high-quality and effective solutions to the ophthalmic community."

The excimer laser complements the ZEISS VISUMAX 800 with ZEISS SMILE pro, extending ZEISS' LVC market leadership with treatment for myopia, hyperopia, and mixed astigmatism.

DUBLIN, Calif. and JENA, Germany, Jan. 13, 2025 /CNW/ -- ZEISS Medical Technology announced today that the MEL® 90 received approval from the U.S. Food and Drug Administration (FDA), giving the excimer laser technology simultaneous approval for all three major indications, including myopia, hyperopia and mixed astigmatism (a condition where both hyperopic and myopic correction is required). The ZEISS MEL 90 fully integrates into the Corneal Refractive Workflow to offer U.S. surgeons a fast, reliable, and streamlined surgery experience, complementing the VISUMAX® 800 with SMILE® pro from ZEISS to help further broaden a surgeon's refractive business with improved patient attraction and positive clinical outcomes.  

  Showcasing at AAO 2024:

ZEISS VisioGen offers a cutting-edge, AI-driven solution designed to enhance refractive patient communication and streamline clinic operations.ZEISS Milestone: Celebrating more than 10 million eyes treated with lenticule extraction solutions utilizing ZEISS SMILE and ZEISS SMILE pro.ZEISS marked its 25th year of leadership in defining optical biometry, with ZEISS IOLMaster biometers becoming the most commonly used biometers in the ophthalmic world.ZEISS MICOR 700 puts the future of lens extraction in the hands of surgeons as the first hand-held lens removal device with ultrasound-free operation; the FDA-cleared device is available in the U.S.Expanding the ZEISS Retina Workflow, now to include advanced vitreoretinal surgical solutions from DORC.Next-generation ZEISS VISULAS combi and green therapeutic lasers receive FDA clearance.

The ZEISS MICOR 700 uses the ZEISS NULEX (non-ultrasonic lens extraction) procedure to help surgeons broaden their intraocular working space, minimizing risk to surrounding eye structures and increasing operating room efficiency.

DUBLIN, Calif. and JENA, Germany, Sept. 26, 2024 /CNW/ -- ZEISS Medical Technology today announced the broad U.S. distribution of the MICOR® 700 from ZEISS, reinventing lens extraction with the first hand-held lens removal device with ultrasound-free operation, providing a sustainable solution with a low initial investment to help surgeons broaden their intraocular working space. Creating a gentler patient experience, the ZEISS MICOR 700 offers a revolutionary approach to lens removal, including patented crystalline lens extraction technology, a blunt and rounded tip design, and a single-use "plug & play" system with a minimal operating room (O.R.) footprint. The ZEISS MICOR 700 will be demonstrated at the American Academy of Ophthalmology (AAO) conference from Oct. 19 – 21, 2024, in Chicago.

Showcasing at EURETINA 2024: ZEISS will highlight new surgical innovations and artificial intelligence (AI) tools for retinal patient care, helping doctors diagnose and treat patients efficiently and effectively: 

THE FUTURE OF VITREORETINAL SURGERY: Demonstrating the ZEISS ARTEVO 850 3D digital visualization system, Single-use Lenses for ZEISS RESIGHT, and the EVA NEXUS surgical system from DORC.AI ADVANCEMENTS FOR RETINA PATIENTS: CIRRUS PathFinder introduces a paradigm shift in the ability to streamline OCT data review, including large amounts of OCT scans flagging macular B-scans that may require closer review.SIMPLIFIED SURGICAL VIDEO MANAGEMENT: Showing a digital application for experiencing 3D videos and more on the Apple Vision Pro, offering surgery video review, analysis, and sharing post-surgery.